Last reviewed · How we verify
Voriconazole clinical practice
Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Esophageal candidiasis, Candidemia in non-neutropenic patients.
At a glance
| Generic name | Voriconazole clinical practice |
|---|---|
| Sponsor | Instituto de Investigación Hospital Universitario La Paz |
| Drug class | Triazole antifungal |
| Target | Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Voriconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This leads to depletion of ergosterol, a critical component of the fungal cell membrane, causing membrane instability and fungal cell death. It has broad-spectrum activity against many clinically important fungi including Aspergillus, Candida, and Cryptococcus species.
Approved indications
- Invasive aspergillosis
- Esophageal candidiasis
- Candidemia in non-neutropenic patients
- Serious Candida infections (intra-abdominal, bladder wall, kidney, peritonitis)
- Scedosporium and Fusarium infections in immunocompromised patients
Common side effects
- Visual disturbances (blurred vision, photopsia)
- Hepatotoxicity (elevated liver enzymes)
- Rash
- Photosensitivity
- Headache
- Hallucinations
- QT prolongation
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: